AMCR vs TSLA

AMCR's deterministic health score is stable with a Piotroski F-Score of 6/9, indicating moderate financial strength, though the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($29.87) and intrinsic value ($10.92), supported by a high forward P/E of 9.96 despite a trailing P/E of 28.38, suggesting optimism around earnings recovery. While revenue growth is robust (71.3% YoY), earnings growth is negative (-14.4% YoY), and the dividend payout ratio is dangerously high at 169.44%, raising sustainability concerns. Analysts are strongly bullish with a $55.01 target price, but weak recent earnings beats (1 of last 4) and bearish technicals (0/100) create conflicting signals.

Tesla's deterministic health is stable with a Piotroski F-Score of 4/9, but its valuation is fundamentally disconnected from current performance. The Graham Number ($22.85) and Intrinsic Value ($7.42) indicate extreme overvaluation relative to the current price of $343.25. With negative YoY revenue growth (-3.10%) and a collapse in earnings growth (-60.60%), the P/E ratio of 323.82 is unsustainable. Technical trends and insider activity are both strongly bearish, suggesting a significant correction is likely.